Abstract: Provided are: an antibody which specifically binds to and neutralizes USAG-1 or an antigen-binding fragment thereof; and a pharmaceutical composition containing the antibody or the antigen-binding fragment.

Abstract: An object of the present invention is to provide a method for producing T cells or NK cells, a culture medium for culturing T cells or NK cells, a method for culturing T cells or NK cells, a method for maintaining the undifferentiated state of undifferentiated T cells, and a growth promoter for T cells or NK cells, which are capable of efficiently proliferating T cells or NK cells and maintaining the state of the cells (for example, undifferentiated property). The present invention relates to a method for producing T cells or NK cells including culturing T cells or NK cells in a culture medium containing a bisbenzylisoquinoline alkaloid represented by formula (X-1) or formula (X-2) or a compound resulting from cleavage of one ether bond thereof or a pharmaceutically acceptable salt thereof, and the like.

Abstract: Technical Problem The purpose of the present invention is to provide a method which enables sex selection in a non-human animal, and enables a coming individual to have no recombination gene, and a transgenic non-human animal giving birth to individuals of only one sex, which is used in the method. Solution to Problem The present disclosure relates to a male transgenic non-human animal in which one of an X chromosome and a Y chromosome comprises an exogenous embryonic death induction gene operatively connected to a drug-responsive promoter. The present disclosure also includes a method for producing a male transgenic non-human animal for sex selection.

Abstract: A brain measurement apparatus configured to generate an MR image and a brain's magnetic field distribution of a subject includes: an MRI module having a transmission coil configured to transmit a transmission pulse toward the subject and a detection coil configured to detect a nuclear magnetic resonance signal generated in the subject by the transmission pulse; an optically pumped magnetometer configured to detect a brain's magnetic field of the subject; a generator configured to generate the MR image based on the nuclear magnetic resonance signal detected by the detection coil and generating the brain's magnetic field distribution based on the brain's magnetic field detected by the optically pumped magnetometer; a marker displayed on the MR image generated by the generator; and a helmet-type frame to which the detection coil, the optically pumped magnetometer, and the marker are attached and which is attached to a head of the subject.

Abstract: A pigment of the present invention is a compound represented by General Formula (1) or General Formula (2) (in the above-described formulae, M is Sn or Ge, X is C or N, R1 is an alkyl group or a phenyl group, Y1 and Y2 are each hydrogen, a halogen group, a methyl group, an alkoxy group, a phenyl group, a diphenylamide group, a thiophenyl group, or a phenylethynyl group, and Z is a single bond or represented by Formula (3), where R2 is an alkyl group or a phenyl group).

Abstract: A brain measurement apparatus includes: a magnetoencephalograph module having a cell, a pump laser configured to emit pump light, a probe laser configured to emit probe light to a sensitivity region intersecting the pump light in the cell, an optical sensor group configured to detect a polarization plane angle of the probe light having passed through the sensitivity region, and a bias magnetic field coil configured to apply a bias magnetic field; and an MRI module having a transmission coil for transmitting an RF pulse of a predetermined frequency, and a receiver coil configured to detect a nuclear magnetic resonance signal generated by transmission of the RF pulse. The magnetoencephalograph module and the MRI module are surrounded by a magnetic shield including a soft magnetic material.

Abstract: An optically pumped magnetometer includes a cell, a pump light incidence unit causing pump light to be incident on a sensitivity region inside the cell in a first direction, a probe light incidence unit causing probe light for detecting change in electron spins to be incident on the sensitivity region in a direction intersecting the first direction, a bias magnetic field coil applying a bias magnetic field in the first direction to the inside of the cell and determining a resonance frequency of the electron spins, a gradient correction coil correcting a gradient of the bias magnetic field, an electron spin tilting unit tilting a rotation axis direction of the electron spins, an optical sensor detecting the probe light having passed through the sensitivity region, and a magnetic field measuring unit measuring a magnetic field strength related to the sensitivity region based on an output of the optical sensor.

Abstract: A brain measurement apparatus includes: a magnetoencephalograph module having a cell; a pump laser configured to emit pump light; a probe laser configured to emit probe light; an optical sensor group configured to detect a polarization plane angle of the probe light having passed through the sensitivity region; a bias magnetic field coil configured to apply a bias magnetic field; and bias magnetic field gradient correction coils configured to correct a gradient of the bias magnetic field; and an MRI module having a transmission coil for transmitting an RF pulse of a predetermined frequency and a receiver coil configured to detect a nuclear magnetic resonance signal. At least one of the coil that applies a static magnetic field and the coil that applies a gradient magnetic field is configured by the same coil as the bias magnetic field coil or the bias magnetic field gradient correction coils.

Abstract: Provided is a method for inducing T cells for a cell-based immunotherapy, comprising the steps of: (1) providing Rag 1 and/or Rag 2 gene knockout human pluripotent stem cells bearing genes encoding a T cell receptor specific for a desired antigen, and (2) inducing T cells from the pluripotent stem cells of step (1). Further provided are a cell-based immunotherapy method that uses the T cells for the cell-based immunotherapy and an iPS cell bank for the cell-based immunotherapy.

Abstract: The disclosure provides a composition for improving cardiac function comprising a compound of formula (I) or an ester, oxide, prodrug, pharmaceutically acceptable salt, or solvate thereof. The disclosure also provides a composition for treating heart failure comprising a compound of formula (I) or an ester, oxide, prodrug, pharmaceutically acceptable salt, or solvate thereof.

Abstract: A molded article including a plant material is produced by a production method including: mixing a plant material containing lignocellulose with an organic acid; dissolving the plant material in the organic acid to produce a lignocellulose solution; and removing a liquid component from the lignocellulose solution to produce a solid content. This plant material is an unused portion of an agricultural crop. The molded article including a plant material contains lignocellulose derived from the plant material as a main component. This lignocellulose has a higher-order structure similar to the plant material. A laminate includes the molded article including the plant material and a sheet laminated on the molded article. The peel strength between the molded article and the sheet is 0.005 MPa or higher.

Abstract: The present invention provides a method for producing, from pluripotent stem cells, neural crest cells specialized for differentiation into a mesenchymal lineage, wherein the method includes: 1) a step for culturing pluripotent stem cells under xeno-free and feeder-free conditions in culture broth containing an ALK inhibitor and a GSK-3? inhibitor to obtain neural crest cells; and 2) a step for culturing the neural crest cells under xeno-free and feeder-free conditions in culture broth that includes an ALK inhibitor, EGF, and FGF and is substantially free of GSK-3? inhibitor.

Abstract: Peptides, salts thereof, peptide conjugates, and salts thereof having 5 to 15 amino acids and having an amino acid sequence comprising at least 5 consecutive amino acids from the amino acid sequence LSSTQAQQSX1 (SEQ ID) NO: 34).

Abstract: Provided is a neutron shielding material having good light transparency and excellent shielding performance against thermal neutron rays, and a method for producing the same. A neutron shielding material according to the present invention includes a light transmitting material and a boron compound enriched in a boron isotope having a mass number of 10, the neutron shielding material being formed of a molded product having light transparency. Shielding performance against thermal neutron rays is improved by containing a boron compound enriched in a boron isotope having a mass number of 10. As a result, the neutron shielding material can be widely applied to members requiring visibility and neutron blocking properties.

Abstract: A molded article with improved mechanical strength properties and thermal properties, and a method for producing the molded article. A composite molded article (C) comprising a cellulosic nanomaterial (A) and a thermoplastic resin (B), an area under a stress-strain curve of the composite molded article (C) (AUC1) being at least two times an area under a stress-strain curve of a melt-molded article (D) having the same composition as that of the composite molded article (C) (AUC2), wherein the stress-strain curve is a curve drawn with strain (unit: %) on the horizontal axis and stress (unit: MPa) on the vertical axis and obtained by subjecting the composite molded article (C) or the melt-molded article (D) to a tensile test, and the area is an area up to the horizontal axis from under a curved portion of the curve that is from the origin (stress: 0) of the stress-strain curve to a fracture of the composite molded article (C) or the melt-molded article (D).

Abstract: Provided are white lignin, a white lignin-polysaccharide complex, and methods for producing the same. A method for producing white lignin or a white lignin-polysaccharide complex, including: (a) a step of bringing a plant biomass into contact with an alkaline solution to obtain an alkali-treated material; (b) a step of washing the alkali-treated material with a liquid to obtain a washed material; and (c) a step of bringing a solution containing an organic acid into contact with the washed material.

Abstract: An electrode active material, an electrode, an electrochemical device, a module, and a method, each utilizing a fluoride ion reaction to improve the charge-discharge cycle performance, are provided. The electrode active material includes a carbon material. During discharge, a metal fluoride is generated. During charge, a fluoride ion is desorbed from the metal fluoride and reacts with the carbon material to form a C—F bond.

Abstract: A composition containing a lignocellulose derivative contains at least one of the group consisting of a compound containing lignin and a compound containing hemicellulose. The composition may further contain a cellulose derivative in which some or all of hydroxyl groups in cellulose are etherified with an alkyl group having 2 or more carbons. A method for producing the composition includes subjecting a biomass as a raw material containing lignocellulose to an alkali treatment in a solvent; alkylating the lignocellulose by adding an alkylating agent to the alkali-treated biomass as a raw material; and fractionating the alkylated biomass as a raw material. The alkylating agent is an alkyl halide having 2 or more carbons.

Abstract: A motor main body of a switched reluctance motor includes a rotor-having a plurality of rotor salient poles, a stator having a plurality of stator salient poles, a drive winding of each phase wound around stator salient poles of the plurality of stator salient poles, of the phase, and a permanent magnet disposed in a stator yoke. A drive circuit outputs a drive current to the drive winding of each phase to rotate the rotor. A pulse current output circuit outputs a pulse current to be superimposed on the drive current during an application time shorter than an application time of the drive current to the drive winding of each phase.

Abstract: Provided is a pharmaceutical composition that can improve tumor immunogenicity. The present disclosure relates to a pharmaceutical composition containing, as an active ingredient, a splicing controlling compound that modulates the activity of serine/arginine-rich splicing factors (SRSFs).